Abstract 1403P
Background
Sotorasib showed a significant improvement of progression free survival (PFS), safety and quality of life over docetaxel in patients with KRAS p.G12C–mutated advanced non–small-cell lung cancer (NSCLC) in the CodeBreak-200 study. Here we report real-world efficacy and tolerability data from NSCLC patients who received sotorasib within the Italian expanded access program (EAP).
Methods
Sotorasib (960 mg, orally, once daily) was available on physician request for KRAS p.G12C mutant advanced NSCLC patients who were pretreated with standard regimens or unfit for approved therapies. Clinical-pathological and molecular data were collected from the Italian ATLAS real-word registry. Patients underwent CT-scan and responses were evaluated by RECIST criteria. Efficacy and tolerability outcomes have been assessed.
Results
A total of 190 advanced NSCLC patients were treated across 30 Italian centres. The overall patients’ median age was 68 years old (range 32-85). Most patients were male (62%), former (49%) or current smokers (42%), with ECOG performance status 0/1 (84%) and adenocarcinoma subtype (89%). Tumor PD-L1 expression was ≥ 50%, 1-49% and <1% in 25%, 37% and 31% of patients, respectively. Patients had received a median of 2 (0–4) previous lines of systemic therapy, with 44% and 33% of them receiving sotorasib in 2nd and 3rd line, respectively. Overall, response rate was 26% and disease control rate 66%. Median PFS was 6.1 months (95% CI: 5.6 – 9.1). Median overall survival (OS) was 8.2 months (95% CI: 6.7-13.6) without significant differences across the main clinical subgroups [age (< 70 vs ≥ 70 years, p= 0.83), treatment line (1st/2nd vs >2nd, p=0.3), brain metastases (p=0.53)]. Grade 3-4 treatment-related adverse events (TRAEs) occurred in 32 patients (17%), with no significant differences between who received or not previous immunotherapy (16% vs 14%, respectively). The most common TRAEs were hepatotoxicity (12%), diarrhea (3%) and asthenia (1%).
Conclusions
Real-world data from the Italian EAP confirm the activity and tolerability of sotorasib in pre-treated patients with KRAS p.G12C-mutated advanced NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
F. Passiglia: Financial Interests, Advisory Board: AstraZeneca, Janssen, Amgen, Sanofi, Roche, MSD, BMS, BeiGene, Thermo Fisher Scientific. G. Minuti: Financial Interests, Advisory Board: Roche, BMS, AstraZeneca, Gilead, Novartis, Sanofi. E. Bria: Financial Interests, Advisory Board: MSD Oncology, AstraZeneca, Pfizer, Lilly, Bristol Myers Squibb, Roche. S. Pilotto: Financial Interests, Advisory Board: AstraZeneca, Eli Lilly & Co, Boehringer Ingelheim, Merck Sharp and Dohme, Roche, Bristol-Myers Squibb. C. Genova: Financial Interests, Advisory Board: AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Merck-Sharp-Dohme, Roche, Takeda. R. Chiari: Financial Interests, Advisory Board: Takeda. S. Novello: Financial Interests, Advisory Board: Boehringer Ingelheim, AstraZeneca, Pfizer, Merck Sharp & Dohme, Bristol Myers Squibb, Roche, Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20
1411P - Tusamitamab ravtansine plus ramucirumab as 2L therapy or beyond in patients with metastatic NSq NSCLC and high CEACAM5 expression (CARMEN-LC04)
Presenter: Grace Dy
Session: Poster session 20